Valuation: Pharmigene, Inc.

Market Cap 35Cr 1.09Cr 94.39L 87.66L 80.84L 1.52Cr 103.75Cr 1.55Cr 10Cr 4.06Cr 52Cr 4.08Cr 3.99Cr 173.28Cr P/E 2024
-8.68x
P/E 2025 -6.84x
Enterprise Value 92Cr 2.84Cr 2.47Cr 2.29Cr 2.11Cr 3.98Cr 271.27Cr 4.05Cr 27Cr 11Cr 134.73Cr 11Cr 10Cr 453.08Cr EV / Sales 2024
10.1x
EV / Sales 2025 5.35x
Free-Float
49.29%
Yield 2024 *
-
Yield 2025 -
1 day-0.29%
Current month-3.85%
1 month-3.85%
3 months-30.10%
6 months-30.79%
Current year-29.39%
1 week 6.33
Extreme 6.33
7.05
1 month 5.9
Extreme 5.9
9.35
Current year 5.9
Extreme 5.9
11.85
1 year 5.9
Extreme 5.9
14.1
3 years 5.9
Extreme 5.9
25.7
5 years 5.9
Extreme 5.9
25.7
10 years 5.9
Extreme 5.9
36
Manager TitleAgeSince
Chief Executive Officer 67 04/11/2019
Chief Operating Officer 49 04/11/2019
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 67 -
Director/Board Member 35 04/11/2019
Director/Board Member 65 07/08/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.29%0.00%-36.45%-70.63% 1.09Cr
-24.17%-19.41%+94.05%+66.19% 477Cr
-6.91%+1.75%+121.29%+168.48% 384.61Cr
+3.44%+3.61%-27.51%-36.11% 209.38Cr
-12.47%-17.23%+60.70%-43.11% 209.41Cr
+13.11%+16.80%+253.11%+297.62% 196.82Cr
-3.93%-3.48%+178.85%-42.31% 100Cr
+6.96%-2.36%-9.88%+25.41% 80Cr
+1.29%+2.60%-37.77%-13.45% 50Cr
+7.90%+0.67%+1.90% - 42Cr
Average -1.56%-3.25%+59.83%+39.12% 175.04Cr
Weighted average by Cap. -7.46%-3.07%+93.37%+79.27%

Financials

2024 2025
Net sales 12Cr 35.9L 31.18L 28.96L 26.71L 50.3L 34Cr 51.22L 3.43Cr 1.34Cr 17Cr 1.35Cr 1.32Cr 57Cr 20Cr 61.58L 53.49L 49.67L 45.81L 86.29L 59Cr 87.85L 5.88Cr 2.3Cr 29Cr 2.31Cr 2.26Cr 98Cr
Net income -8.29Cr -25.53L -22.17L -20.59L -18.99L -35.77L -24Cr -36.42L -2.44Cr -95.45L -12Cr -95.87L -93.77L -41Cr -7.3Cr -22.49L -19.53L -18.14L -16.73L -31.51L -21Cr -32.08L -2.15Cr -84.08L -11Cr -84.45L -82.6L -36Cr
Net Debt 46Cr 1.41Cr 1.23Cr 1.14Cr 1.05Cr 1.98Cr 134.66Cr 2.01Cr 13Cr 5.27Cr 67Cr 5.3Cr 5.18Cr 224.9Cr 57Cr 1.75Cr 1.52Cr 1.42Cr 1.31Cr 2.46Cr 167.53Cr 2.5Cr 17Cr 6.56Cr 83Cr 6.59Cr 6.45Cr 279.8Cr
Logo Pharmigene, Inc.
Pharmigene Inc is mainly engaged in drug gene diagnosis, functional medical testing services and agency sales of laboratory equipment and consumables. The Company mainly engages in field of genomics science, developing professional drug genetic diagnostic kits, testing technologies, and overall solutions for the research and development of drug genomics in precision medicine. The Company's molecular diagnostic products mainly include AutoEx16 automatic nucleic acid extractor, Clopidogrel drug effectiveness gene CYP2C19*2&*3 test kit, SGE 1502 test suite, SGE 3101 test suite, SGE 5701 test suite, Sega 5801 test kit, SGE B27 test kit, SGE whole blood calculation and extraction kit and others. Testing services include drug genetic testing projects, functional medical testing projects and personalized genetic testing. The Company mainly distributes its products in Taiwan market and other markets.
Employees
-
Date Price Change Volume
31/26/31 NT$6.990 -0.29% 1,310
30/26/30 NT$7.010 +0.57% 7,040
29/26/29 NT$6.970 -0.43% 1,07,165
28/26/28 NT$7.000 -0.57% 78,475
27/26/27 NT$7.040 -0.14% 13,140
  1. Stock Market
  2. Stocks
  3. 7595 Stock